-
Most Recent
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Biotech’s Regeneron Is a New Game Changer Buy
Biotech's Regeneron is a strong buy based on its existing Eylea drug for macular degeneration, but the company also has a solid pipeline of products.
My Favorite Sector for Summer: Biotech
Stocks can suck in the summertime, but not every sector is doomed: Here's why biotech could be the season's sweetheart, and which stocks look hot.
7 Biotech Stocks to Add to Your Portfolio
The biotech business is working overtime to find the next breakthrough drugs and treatments for a population that gets older every day.
4 Stocks Buffett May Be Buying in Europe
A look at the Oracle's buying behavior in the past clues you in to where his cash is likely being funneled now.
Gilead Sciences’ HIV Drugs Clear a Hurdle
Full FDA approval should come next -- but if not, watch out, because Gilead is very heavily dependent on its HIV drug lineup, and patents will be expiring.
Obesity: The Next Investment Driver
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.
Pfizer is Still a Pharmaceutical-Giant Buy
Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio.
Pfizer: Profits Drop, Beat Forecasts
Pfizer's first-quarter earnings and revenue declined, led by dropping sales for Lipitor, but beat analysts’ forecasts, even as it lowered its outlook.
Watson Pharmaceuticals Is No Ordinary Generic
Watson Pharmaceuticals is an outstanding company that grows earnings and revenues every year in the tough generic pharma space. Consider this a top buy.
AstraZeneca CEO Resigns, Shares Drop
CEO David Brennan departs after the company reported lower earnings and sales for the last quarter and a diminished outlook for the year.
Why Biotech Investing Is So Hard
It spikes wildly when gaining, plunges quickly when falling -- and normal strategies don't apply.
Invest Smarter in the New Biotech Landscape
Big phara and biotech companies are slowly becoming one and the same. Investors can profit from the merge with solid research and timing.
6 Biotech Stocks to Buy Today
Biotech stocks rise and fall on the success of research and getting new products to market. Here are 6 biotechs worth investing into your portfolio.
Will JNJ Rise From the Ashes?
No need to mince words -- Johnson & Johnson is in a pretty good mess right now. But new CEO Alex Gorsky might have the tools to turn things around.
Abbott Laboratories Is Cheaper Than You Think
Abbott Labs financial statements provide information on earnings per share that suggest the stock is undervalued, with a possible P/E ratio better than market
Stock Pick of The Day: Dyax
Dyax is a maker of anti-inflammation drugs, an area with a growing base of patients. While in the early stages of growth, the company shows great promise.
5 Global Stock Buys and 2 Sells
There a number of outstanding opportunities in European stocks, as long as you can do the work to find them. Here are 5 top performers to start with now.
3 New Biotech Buys for Your Portfolio
Three new biotech buys lead the way for additions to your portfolio as we head into April.
Wait for Monsanto to Slide
The stock has much to recommend it -- except its inflated valuation. Here's why you should wait to buy in.
